RedHill Biopharma is dedicated to the commercialization and development of proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and infectious diseases.

Development Pipeline

RedHill's pipeline of  late-stage, proprietary development programs includes multiple Phase 3 and Phase 2 programs targeting gastrointestinal disease, oncology and infectious diseases. 

Please see RedHill Biopharma's expanded acceess program here.

Commercial Products

RedHill has assembled an experienced specialty gastrointestinal-focused commercial team, with a proven track-record, to lead its U.S. commercial operations, headquartered in Raleigh, NC.

RedHill promotes several gastrointestinal specialty products in the U.S.: 

Movantik® (naloxegol) – prescription drug

Talicia® (omeprazole magnesium, amoxicillin and rifabutin) – prescription drug

Aemcolo® (rifamycin) – prescription drug